Your browser doesn't support javascript.
loading
Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement.
Kato, Takeharu; Itonaga, Hidehiro; Taguchi, Jun; Makiyama, Junya; Fujioka, Machiko; Taguchi, Masataka; Horai, Makiko; Sawayama, Yasushi; Niino, Daisuke; Imaizumi, Yoshitaka; Hata, Tomoko; Yoshida, Shinichiro; Sakamoto, Kana; Takeuchi, Kengo; Ohshima, Koichi; Miyazaki, Yasushi.
Afiliación
  • Kato T; Department of Hematology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
  • Itonaga H; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Taguchi J; Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
  • Makiyama J; Department of Hematology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
  • Fujioka M; Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Taguchi M; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Horai M; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Sawayama Y; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Niino D; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Imaizumi Y; Department of Pathology, Nagasaki University Hospital, Nagasaki, Japan.
  • Hata T; Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
  • Yoshida S; Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
  • Sakamoto K; Department of Hematology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
  • Takeuchi K; Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ohshima K; Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Miyazaki Y; Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Leuk Res Rep ; 11: 31-33, 2019.
Article en En | MEDLINE | ID: mdl-31061790
A 62-year-old male was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with a MYC rearrangement. Four months after the first unrelated bone marrow transplantation (BMT), he developed the relapsed BPDCN. After the achievement of partial remission following re-induction therapy, he underwent a second BMT from another unrelated donor, and experienced complete remission with grade II acute graft-versus-host disease and moderate chronic graft-versus-host disease. He remains alive in complete remission more than 71 months after the second BMT. These results suggested that donor change at the second transplantation may represent a considerable therapeutic option for patients with relapsed BPDCN.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Leuk Res Rep Año: 2019 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Leuk Res Rep Año: 2019 Tipo del documento: Article País de afiliación: Japón